The Trials Acceleration Programme by Leukaemia & Lymphoma Research

At the 20th Congress of the European Hematology Association (EHA), Charles Craddock, FRCPath, FRCP, DPhil, BMBCh, of the University of Birmingham, Birmingham, UK, discusses the Trials Acceleration Programme (TAP) initiative by Leukaemia & Lymphoma Research. TAP aims to accelerate the clinical development of new therapies for patients with blood cancer through the creation of a network of leading treatment centers around the UK.

Share this video  
12th June 2015